Karyopharm Q1 net loss narrows

Karyopharm Therapeutics

14/05/2026 12:42

Overview

U.S. cancer therapy maker's net loss for Q1 narrowed, reflecting improved operating efficiency and disciplined cost management

Outlook

Karyopharm reaffirms 2026 total revenue guidance of $130 mln to $150 mln

Result Drivers

GROSS-TO-NET ADJUSTMENTS - Higher net product revenue was primarily driven by lower gross-to-net adjustments, including reduced discounts and product returns

COMPETITIVE PRESSURE - Demand for XPOVIO declined yr/yr due to new competitive entrants, according to the company

INTERNATIONAL ROYALTIES - Modest growth in royalty revenue from expanded global patient access and additional ex-U.S. approvals

Company press release: ID:nPn2Dhgsa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$22.39 mln
Q1 Operating Expenses
$61.83 mln
Q1 Operating Income
-$26.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 69.5% above its May 13 closing price of $8.85

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)